Modeling & Meta-Analysis

Simulating Outcomes Beyond Trials

Models & Meta-Analyses (MMA) are powerful tools for making comprehensive assessments of the costs and benefits of healthcare interventions beyond clinical trials. Health economic models provide vital information to inform allocation of available resources for maximizing health benefits. Meta-analyses are powerful tools for synthesizing multiple studies to improve the precision and relevance of clinical and health outcomes data.

Our models are designed to be user-friendly and easily adaptable. We use Excel-based interfaces, web-based dashboards in dedicated software, and detailed, transparent documentation of complex simulations to make our models accessible for the intended audience.

We offer a full range of MMA services, including:

  • Economic models to support reimbursement submissions around the world
  • Early models designed to inform commercial decision-making
  • Population-based dynamic transmission models
  • Global core models and country adaptations
  • Microsimulation of individual patient disease progression, treatment pathways, and outcomes
  • Simple calculators illustrating costs and outcomes
  • User-friendly graphical user interfaces
  • Nationally representative estimates of the budget impact to government payers
  • Models supporting economic value messages for AMCP dossiers
  • Graphical user interfaces and web-based applications for use in payer discussions
  • Systematic literature reviews and network meta-analyses to support economic modeling and HTA submissions
  • Clinical landscape and data comparability assessments
  • Indirect treatment comparisons of non-randomized data
  • Network meta-analysis and indirect treatment comparison of survival data
  • Meta-analysis of epidemiologic and other non-clinical data
  • Matching adjusted indirect comparisons
  • Simulated treatment comparisons
  • Survival analysis and extrapolation
  • Trial-based economic models

Why Pharmerit?

  • High-quality deliverables meeting HTA requirements

  • Multidisciplinary, dedicated teams including senior team members and experienced clinicians working on value communication/dossier development

  • Experienced HEOR and clinical researchers with a strategic focus, who are able to combine and interpret burden of illness, treatment pathway, clinical and economic evidence in order to support a product’s value communication and reimbursement strategy

  • Partnering with clients on products and portfolios from clinical development, launch, and post-launch

  • Innovative solutions to present and communicate the value of your product by interactive tools to visualize and highlight findings

Resources

”We were looking for skills and resources to address our question for an indirect comparison/network meta-analysis. Pharmerit has successfully addressed our research needs. We already had positive experience in working with them as a preferred provider. Pharmerit provides clear and smooth communication, good staff capabilities and complies with project timelines.”

Associate Director, Health Economics, Bristol-Myers Squibb

Meet Our Modeling & Meta-Analysis Team

Modeling & Meta-Analysis Publications

Measuring Recovery in Opioid Use Disorder: Clinical Utility and Psychometric Properties of the Treatment Effectiveness Assessment.

Authors: W Ling, VR Nadipelli, C Solem, D Farabee, NA Ronquest, B Perrochet, SM Learned, CG Deshpande, C Heidbreder

...

 Continue Reading
Cures

Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?

Cures

Authors: Adrian Towse, MA, MPhil, Elisabeth Fenwick, PhD

Payers are concerned that one-off “cures” bring great uncertainty with the consequential risk of incorrect adoption decisions, and significant budget impact from large one-off payments....

 Continue Reading
HIV
chemotherapy

Cost-Effectiveness of a Fixed Combination of Netupitant and Palonosetron (NEPA) Relative to Aprepitant Plus Granisetron (APR + GRAN) for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV): A Trial-Based Analysis

chemotherapy

Authors: M Botteman, K Nickel, S Corman, M Turini, G Binder

Chemotherapy-induced nausea and vomiting (CINV) are among the most common and debilitating side effects patients experience during chemotherapy and are associated with considerable acute care use and healthcare cost....

 Continue Reading
infant
chemotherapy

Budget Impact of Netupitant/palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting

chemotherapy

Authors: SH Park, G Binder, S Corman, M Botteman

Chemotherapy-induced nausea and vomiting (CINV) are among the most common and debilitating side effects patients experience during chemotherapy and are associated with considerable acute care use and healthcare cost....

 Continue Reading

Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson’s Disease: Results from a pooled meta-analysis

Authors: David Standaert, Vardhaman Patel, Sonya Snedecor, Sandeep Thakkar, Yash J. Jalundhwala, Pavnit Kukreja, David Kratochvil, Yanjun Bao, Rajesh Pahwa

To evaluate short-term and long-term impact of carbidopa-levodopa enteral suspension (CLES) on quality of life (QoL) and activities of daily living (ADL) in patients with advanced Parkinson’s Disease (APD)....

 Continue Reading
Invasive Fungal Infections

Treatment of Immunocompromised Patients with Suspected Invasive Fungal Infections: Economic Analysis of Diagnostic-Driven Versus Empirical Strategies in Algeria and Egypt

Invasive Fungal Infections

Authors: Z Kaci, L Shalaby, S Kamal, N Boudjerra, X Gao, M Xue, S Ait Belkacem, A Gab Allah Ibrahim, R Kotb, C Charbonneau.

...

 Continue Reading
Partner with Pharmerit

Partner with Pharmerit

Contact Us